Efficacy of molecularly targeted agents given in the randomised trial SHIVA01 according to the ESMO Scale for Clinical Actionability of molecular Targets. (November 2019)

• Record Type: Journal Article
• Authors: Moreira, A.; Masliah-Planchon, J.; Callens, C.; Vacher, S.; Lecerf, C.; Frelaut, M.; Borcoman, E.; Torossian, N.; Ricci, F.; Hescot, S.; Sablin, M.P.; Tresca, P.; Loirat, D.; Melaabi, S.; Trabelsi-Grati, O.; Pierron, G.; Gentien, D.; Bernard, V.; Vincent Salomon, A.; Servant, N.; Bieche, I.; Le Tourneau, C.; Kamal, M.
• Is Part Of: European journal of cancer. Volume 121(2019)
• Page Start: 202
• Page End: 209
• Publication Date: 2019-11
• Subjects: Molecularly targeted agents -- ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) -- Actionable molecular alterations -- Treatment algorithms -- Precision medicine -- SHIVA01; Cancer -- Periodicals; Neoplasms -- Periodicals; Cancer -- Périodiques; Cancer; Tumors; Electronic journals; Periodicals; Electronic journals; 616.994
• DOI: 10.1016/j.ejca.2019.09.001
• Languages: English
• ISSNs: 0959-8049

Abstract

Abstract: Background: A randomised trial SHIVA01 compared the efficacy of matched molecularly targeted therapy outside their indications based on a prespecified treatment algorithm versus conventional chemotherapy in patients with metastatic solid tumours who had failed standard of care. No statistical difference was reported between the two groups in terms of progression-free survival (PFS), challenging treatment algorithm. The European Society for Medical Oncology (ESMO) Scale for Clinical Actionability of molecular Targets (ESCAT) recently defined criteria to prioritise molecular alterations (MAs) to select anticancer drugs. We aimed to retrospectively evaluate the efficacy of matched molecularly targeted agents (MTAs) given in SHIVA01 according to ESCAT tiers. Patients and methods: MAs used in SHIVA01 were retrospectively classified into ESCAT tiers, and PFS and overall survival (OS) were compared using log-rank tests. Results: One hundred fifty-three patients were treated with matched MTAs in SHIVA01. MAs used to allocate MTAs were classified into tiers II, IIIA, IIIB and IVA according to the ESCAT. Median PFS was 2.0 months in tier II, 3.1 in tier IIIA, 1.7 in tier IIIB and 3.2 in tier IVA (p = 0.13). Median OS in tier IIIB was worse than that in tiers II, IIIA and IVA (6.3 months versus 11.7, 11.2 and 12.1, p = 0.002). Conclusions: Most MAs used to allocate therapy in SHIVA01 were shown to improve outcomes in other tumour types (tier IIIA). Worst outcome was observed in patients treated based on another type of alteration than the one reported to improve outcomes (tier IIIB), highlighting the crucial impact of the type of the alterations beyond the gene and the signalling pathway. Highlights: Most alterations used to allocate therapy in SHIVA01 had low actionability according to the ESMO Scale for Clinical Actionability of molecular Targets. Worst outcome was reported in patients treated based on another type of alteration than the one reported to improve outcome. The results highlight the crucial impact of alterations type beyond the gene and/or the signalling pathway.